The combined evidence suggests that the increase of the 65 kDa APP-BP1 in AD is beneficial to neurons by inhibiting Aβ42 genesis and points to a potential therapeutic strategy of upregulating APP-BP1 modification. Here, APP is linked to Alzheimer disease.